Earlier this year (NASDAQ:BMTI) BioMimetic submitted device applications for the European Union (EU) approval of Augment Bone Graft and GEMESIS (EU trade name for GEM 21S®, a dental product that the Company developed and sold to Luitpold Pharmaceuticals, Inc.). The Company is seeking approval in Europe under the CE marking procedure, which is designed to provide a single marketing approval for all countries included in the EU. The Company expects regulatory decisions on both European applications in 2012.
Share This Post:
any stock i buy or sell could be halted and go to zero at any time.if you can not lose it dont trade it.